tw0122
1 week ago
Nice one .. SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach enabled by Telesis Bioβs Gibson SOLA enzymatic reagent platform running on Beckman Coulter Life Sciences automation to ensures rapid, reliable, and highly scalable production of extremely high-fidelity DNA, empowering researchers to achieve greater productivity and innovation in a wide array of discovery applications.
XenaLives
7 months ago
This one scares the crap out of me...
Imagine replication of COVID ( or the next worst thing) with out a biological matrix.
December 5, 2023 | LIVE WEBINAR
Unlocking the Potential of mRNA as a Tool for Immuno-Oncology Therapy Discovery and Development
Immuno-oncology is a rapidly growing area for therapeutic development. With the adoption of various autologous cell therapies and an increased focus on more broadly applicable allogeneic treatments and multi-specific therapies, the complexity of these development activities is also increasing. With this drive to increased complexity and the inherent risks associated with potential failure in Phase 1 clinical trials, it is critical to have a solid scientific foundation for the development of these next-generation immunotherapies. This talk will focus on how to overcome the limitations associated with traditional viral vector based recombinant TCR gene expression to build hundreds of candidates a week, resulting in improved confidence in screening and lead optimization. With the direct use of mRNA to drive transient modulation of cellular phenotypes, potential candidates can be screened quickly and cost-effectively. Come and learn how immuno-oncology researchers are automating synthetic biolological...
$TBIO Granted EUR Patent #3503915 For "GENETICALLY ENGINEERED VIBRIO NATRIEGENS (HOST ORGANISM FOR CLONING AND MANIPULATING DNA)".https://t.co/9dekeJkgGu pic.twitter.com/Mj3hMaJPML— Patent_Stocks (@US_Patent_Plays) February 22, 2024